Gliadel Ad Features Misleading Efficacy Claims – DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-page journal ad includes unsubstantiated claims that high-grade malignant melanoma treatment “works at day 1,” FDA says.
You may also be interested in...
MGI Purchase Of Guilford Will Create Two-Product Acute Care Sales Force
Reps will target surgeons and anesthesiologists to promote Aloxi post-operative nausea treatment and the pipeline sedative Aquavan. The $177.5 mil. merger is expected to close in the fourth quarter.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.